NPPB and hydrops fetalis: In the context of the ongoing conundrum around how best to prevent the syndrome,23 in the 2017 ACC/AHA/HFSA focused update, biomarker NT‐proBNP‐based screening in those at risk of developing HF received a Class IIa recommendation (level of evidence: B–R).